Lista de obras -

A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection

artículo científico publicado en 2017

A novel strategy to adapt SHIV-E1 carrying env from an RV144 volunteer to rhesus macaques: coreceptor switch and final recovery of a pathogenic virus with exclusive R5 tropism

artículo científico publicado en 2018

A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis

artículo científico publicado en 2002

A review of epidemic preparedness for influenza through local vaccine production: national security for Thailand

artículo científico publicado en 2019

Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand

artículo científico publicado en 2015

Aggregate complexes of HIV-1 induced by multimeric antibodies

artículo científico publicado en 2014

Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved

artículo científico publicado en 2014

Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women

artículo científico publicado en 2017

Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family

artículo científico publicado en 2012

Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion

artículo científico publicado en 2012

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.

artículo científico publicado en 2017

Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency

artículo científico publicado en 2020

COMPASS identifies T-cell subsets correlated with clinical outcomes

artículo científico publicado en 2015

Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations

artículo científico publicado en 2018

Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens

artículo científico publicado en 2016

Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial

artículo científico publicado en 2015

Correction: Estimation of the Total Parasite Biomass in Acute Falciparum Malaria from Plasma PfHRP2

artículo científico publicado en 2005

Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2

artículo científico publicado en 2005

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial

artículo científico publicado en 2014

HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions

scientific article published on 30 January 2020

HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees

artículo científico publicado en 2018

HIV-1 specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galcer Blocking and Phagocytosis

artículo científico publicado en 2018

HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities

artículo científico publicado en 2014

HIV-specific antibody-dependent phagocytosis matures during HIV infection.

artículo científico publicado en 2014

HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial

artículo científico publicado en 2014

HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition

artículo científico publicado en 2015

Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques

artículo científico publicado en 2015

Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor

artículo científico publicado en 2015

IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens

artículo científico publicado en 2015

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

artículo científico publicado en 2012

Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses

artículo científico publicado en 2014

Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees

artículo científico publicado en 2013

Machine learning methods enable predictive modeling of antibody feature:function relationships in RV144 vaccinees

artículo científico publicado en 2015

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials

artículo científico publicado en 2012

Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans

article

Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect

artículo científico publicado en 2017

Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection

artículo científico publicado en 2016

Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial

artículo científico publicado en 2013

Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines

artículo científico publicado en 2014

Prophylactic HIV vaccine: vaccine regimens in clinical trials and potential challenges

scientific article published on 20 February 2020

Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial

artículo científico publicado en 2017

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

artículo científico publicado en 2012

Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand

artículo científico publicado en 2011

Selecting participants fairly for controlled human infection studies

artículo científico publicado en 2020

Specific Antibody Responses to Vaccination with Bivalent CM235/SF2 gp120: Detection of Homologous and Heterologous Neutralizing Antibody to Subtype E (CRF01.AE) HIV Type 1 ⬇️

artículo científico publicado el 1 de septiembre de 2003

Stage-dependent production and release of histidine-rich protein 2 by Plasmodium falciparum

artículo científico publicado en 2005

Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee

artículo científico publicado en 2015

The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

artículo científico publicado en 2012

The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope ⬇️

artículo científico publicado el 23 de abril de 2012

Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques

artículo científico publicado en 2016

V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.

artículo científico publicado en 2017

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

artículo científico publicado en 2013

Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination

artículo científico publicado en 2014

Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide

artículo científico publicado en 2014

Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection

artículo científico publicado en 2014

Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG.

artículo científico publicado en 2013

Lista de obras de

A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection

A novel strategy to adapt SHIV-E1 carrying env from an RV144 volunteer to rhesus macaques: coreceptor switch and final recovery of a pathogenic virus with exclusive R5 tropism

A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis

A review of epidemic preparedness for influenza through local vaccine production: national security for Thailand

Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand

Aggregate complexes of HIV-1 induced by multimeric antibodies

Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved

Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women

Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family

Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.

Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency

COMPASS identifies T-cell subsets correlated with clinical outcomes

Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations

Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens

Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial

Correction: Estimation of the Total Parasite Biomass in Acute Falciparum Malaria from Plasma PfHRP2

Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial

HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions

HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees

HIV-1 specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galcer Blocking and Phagocytosis

HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities

HIV-specific antibody-dependent phagocytosis matures during HIV infection.

HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial

HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition

Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques

Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor

IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses

Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees

Machine learning methods enable predictive modeling of antibody feature:function relationships in RV144 vaccinees

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials

Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans

Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect

Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection

Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial

Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines

Prophylactic HIV vaccine: vaccine regimens in clinical trials and potential challenges

Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand

Selecting participants fairly for controlled human infection studies

Specific Antibody Responses to Vaccination with Bivalent CM235/SF2 gp120: Detection of Homologous and Heterologous Neutralizing Antibody to Subtype E (CRF01.AE) HIV Type 1 ⬇️

Stage-dependent production and release of histidine-rich protein 2 by Plasmodium falciparum

Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee

The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope ⬇️

Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques

V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination

Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide

Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection

Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG.